This article describes the outcomes of patients who were treated with tivozanib for advanced renal cell carcinoma (RCC) and provides data to guide sequenci
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
About 3.7 million people are at immediate risk of losing health coverage should the federal government cut funding for Medicaid expansions, as some allies of…
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
Latest News The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16,
Corbin Smith is one of five artists-in-residence at the cancer center
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
January 22, 2025 Learning Objectives: Define the spectrum of contemporary preclinical models of HNSCC. Describe the strengths and weaknesses of contemporary preclinical models of HNSCC.…
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
